Sysyemic Lupus Erythematosus with Multiple Organ Damage

1. Tsokos GC. Systemic lupus erythematosus. N Engl J Med. 2011;365(22):2110-2121. doi:10.1056/NEJMra110035910.1056/NEJMra1100359Search in Google Scholar

2. Mok CC, Lau CS. Pathogenesis of systemic lupus erythematosus. J Clin Pathol. 2003;56(7):481-490. doi:10.1136/jcp.56.7.48110.1136/jcp.56.7.481Search in Google Scholar

3. Siegel M, Lee SL. The epidemiology of systemic lupus erythematosus. Semin Arthritis Rheum. 1973;3(1):1-54. doi:10.1016/0049-0172(73)90034-610.1016/0049-0172(73)90034-6Search in Google Scholar

4. Almaani S, Meara A, Rovin BH. Update on Lupus Nephritis. Clin J Am Soc Nephrol. 2017;12(5):825-835. doi:10.2215/CJN.0578061610.2215/CJN.05780616Search in Google Scholar

5. Ward MM. Changes in the Incidence of End-stage Renal Disease Due to Lupus Nephritis, 1982-1995. Arch Intern Med. 2000;160(20):3136–3140. doi:10.1001/archinte.160.20.313610.1001/archinte.160.20.3136Search in Google Scholar

6. Tang Y, Zhang W, Zhu M, et al. Lupus nephritis pathology prediction with clinical indices. Sci Rep. 2018;8(1):10231. Published 2018 Jul 6. doi:10.1038/s41598-018-28611-710.1038/s41598-018-28611-7Search in Google Scholar

7. Haddon DJ, Diep VK, Price JV, et al. Autoantigen microarrays reveal autoantibodies associated with proliferative nephritis and active disease in pediatric systemic lupus erythematosus. Arthritis Res Ther. 2015;17(1):162. Published 2015 Jun 17. doi:10.1186/s13075-015-0682-610.1186/s13075-015-0682-6Search in Google Scholar

8. Yu F, Haas M, Glassock R, Zhao MH. Redefining lupus nephritis: clinical implications of pathophysiologic subtypes. Nat Rev Nephrol. 2017;13(8):483-495. doi:10.1038/nrneph.2017.8510.1038/nrneph.2017.85Search in Google Scholar

9. Murin S, Wiedemann HP, Matthay RA. Pulmonary manifestations of systemic lupus erythematosus. Clin Chest Med. 1998;19(4):641-viii. doi:10.1016/s0272-5231(05)70108-810.1016/S0272-5231(05)70108-8Search in Google Scholar

10. Kamen DL, Strange C. Pulmonary manifestations of systemic lupus erythematosus. Clin Chest Med. 2010;31(3):479-488. doi:10.1016/j.ccm.2010.05.00110.1016/j.ccm.2010.05.00120692540Search in Google Scholar

11. Webb WR, Gamsu G. Cavitary pulmonary nodules with systemic lupus erythematosus: differential diagnosis. AJR Am J Roentgenol. 1981;136(1):27-31. doi:10.2214/ajr.136.1.2710.2214/ajr.136.1.276779577Search in Google Scholar

12. Ryu JH, Swensen SJ. Cystic and cavitary lung diseases: focal and diffuse. Mayo Clin Proc. 2003;78(6):744-752. doi:10.4065/78.6.74410.4065/78.6.74412934786Search in Google Scholar

13. Newman K, Owlia MB, El-Hemaidi I, Akhtari M. Management of immune cytopenias in patients with systemic lupus erythematosus - Old and new. Autoimmun Rev. 2013;12(7):784-791. doi:10.1016/j.autrev.2013.02.00110.1016/j.autrev.2013.02.00123462431Search in Google Scholar

14. Fanouriakis A, Kostopoulou M, Alunno A, et al. 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus. Annals of the Rheumatic Diseases 2019;78: 736-745.10.1136/annrheumdis-2019-21508930926722Search in Google Scholar

15. Van Vollenhoven RF, Mosca M, Bertsias G, et al. Treat-to-target in systemic lupus erythematosus: recommendations from an international task force. Ann Rheum Dis. 2014;73(6):958-967. doi:10.1136/annrheumdis-2013-20513910.1136/annrheumdis-2013-20513924739325Search in Google Scholar

16. Sarabi ZS, Chang E, Bobba R et al. Incidence rates of arterial and venous thrombosis after diagnosis of systemic lupus erythematosus. Arthritis Rheum 2005;53:60912.10.1002/art.2131416082635Search in Google Scholar

17. Mok CC, Tang SS, To CH, Petri M. Incidence and risk factors of thromboembolism in systemic lupus erythematosus: a comparison of three ethnic groups. Arthritis Rheum 2005;52:27748210.1002/art.2122416142761Search in Google Scholar

18. Bazzan, M., Vaccarino, A. & Marletto, F. Systemic lupus erythematosus and thrombosis. Thrombosis J 13, 16 (2015). doi:10.1186/s12959-015-0043-310.1186/s12959-015-0043-3440732025908929Search in Google Scholar

19. Ramirez GA, Efthymiou M, Isenberg DA, Cohen H. Under crossfire: thromboembolic risk in systemic lupus erythematosus. Rheumatology (Oxford). 2019;58(6):940-952. doi:10.1093/rheumatology/key30710.1093/rheumatology/key30730380105Search in Google Scholar

20. Sultan SM, Begum S, Isenberg DA. Prevalence, patterns of disease and outcome in patients with systemic lupus erythematosus who develop severe haematological problems. Rheumatology (Oxford). 2003;42(2):230-234. doi:10.1093/rheumatology/keg06910.1093/rheumatology/keg06912595615Search in Google Scholar

21. Kokori SI, Ioannidis JP, Voulgarelis M, Tzioufas AG, Moutsopoulos HM. Autoimmune hemolytic anemia in patients with systemic lupus erythematosus. Am J Med. 2000;108(3):198-204. doi:10.1016/s0002-9343(99) 00413-110.1016/S0002-9343(99)00413-1Search in Google Scholar

22. Nossent JC, Swaak AJ. Prevalence and significance of haematological abnormalities in patients with systemic lupus erythematosus. Q J Med. 1991;80(291):605-612.Search in Google Scholar

23. Markowitz GS, D’Agati VD. The ISN/RPS 2003 classification of lupus nephritis: an assessment at 3 years. Kidney Int. 2007;71(6):491-495. doi:10.1038/sj.ki.500211810.1038/sj.ki.500211817264872Search in Google Scholar

24. Houssiau FA, Vasconcelos C, D’Cruz D, et al. Immunosuppressive therapy in lupus nephritis: the Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide. Arthritis Rheum. 2002;46(8):2121-2131. doi:10.1002/art.1046110.1002/art.1046112209517Search in Google Scholar